Please use this identifier to cite or link to this item:
Title: Infliximab Biosimilars: A Promising but Unusual Treatment for Mycobacterial Immune Reconstitution Inflammatory Syndrome in Human Immunodeficiency Virus-Infected Patients.
Issue Date: 2017
Citation: Open Forum Infect Dis.2017;(4)3:ofx164
Abstract: Immune reconstitution inflammatory syndrome can present as a paradoxical reaction after initiation of antiretroviral treatment in patients with severe immunosuppression and underlying infections. Immune reconstitution inflammatory syndrome has often been associated with mycobacteria, and the clinical response to traditional treatment with corticosteroids is not always satisfactory. Consequently, administration of an infliximab biosimilar could lead to an improvement in the clinical status of these patients.
PMID: 28948183
Rights: openAccess
ISSN: 2328-8957
Appears in Collections:Hospitales > H. U. Infanta Leonor > Artículos

Files in This Item:
File Description SizeFormat 
PMC5604167.pdf265.22 kBAdobe PDFThumbnail

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.